TRIO operates under a translational research model led by our Chairman, Dr. Dennis Slamon. Translational research encourages us to create innovative protocols along the most rational development path. TRIO-US, along with UCLA, conducts more than 20 small-scale Phase 1 oncology studies annually, passing on promising therapies to TRIO for additional testing. The research-focused, vertically integrated system helps TRIO guide the next generation of clinical oncology trials.

Through our corporate head office in Edmonton, Canada, our regional offices in Paris, France and Montevideo, Uruguay, and our global network of partners, we conduct our clinical research across the globe. Our offices keep us connected to our extensive network of investigators and research clinics. This global reach allows us to efficiently source patients, speeding up the clinical trial process.

Our services cover the entire clinical research spectrum from study conception to design, execution, data analysis, and distribution of results at all phases of clinical trials. We are experts in oncology, biostatistics, project management, quality assurance, regulatory affairs, monitoring, and information technology. We take immense pride in our work and strive to provide science-driven innovation in all aspects of our operations.

Since TRIO’s creation in 1997 as BCIRG, we have been at the forefront of oncology research. TRIO has successfully conducted more than 25 international studies. This number reflects TRIO’s unyielding focus on trials with the most innovative science and greatest likelihood of success. Our completed registration trials have led to cancer drugs or regimens that have changed the practice of oncology: docetaxel in the early breast cancer setting, trastuzumab together with a non-anthracycline-containing trastuzumab (TCH) regimen in the early HER2+ breast cancer setting, the more recent approval of palbociclib with letrozole in postmenopausal women with metastatic breast cancer, and other breakthrough treatments.

TRIO’s record of success over the past two decades has led to a vast, engaged Investigator Network of over 400 centres in more than 25 countries. In some of these countries, TRIO has established preferred partnerships with national cooperative groups, adding an additional level of engagement and cohesion. TRIO is confident in its ability to accrue rapidly and deliver valuable results because of this Investigator Network and their experience, engagement, high-quality data, and proven record of success.

Our open lines of communication with our Investigator Network ensures that TRIO is up-to-date on current clinical trials in progress around the world. TRIO has maintained long-standing professional connections and worked together with its partner sites on multiple clinical trials. The relationships TRIO has forged with its Investigator Network expedites site activation and ensures a healthy work partnership throughout the duration of clinical trials. If you would like to learn more about joining our network, contact us.

TRIO’s roots are in academia and we retain connections to universities around the world. The members of our Board of Directors and Scientific Committee are not paid for their efforts. This commitment to science draws strong academic investigators to our group, motivated by TRIO’s collaborative, intellectually-driven translational research. Because of our strong academic focus, TRIO and its investigators contribute to the concept, protocol design, analysis, interpretation, presentation and publication of a study, and work closely with the trial sponsor.

TRIO was originally established in 1997 as BCIRG (Breast Cancer International Research Group), immediately helping to confirm docetaxel’s role in breast cancer treatment. In 1999, BCIRG changed its name to CIRG (Cancer International Research Group), to reflect the expanded range of histologies in its clinical trials. CIRG merged with its associated organizations at UCLA, TORL and Translational Oncology Research International, in 2005. As its international presence continued to expand, the name was changed to TRIO in 2011.

TRIO has grown into a worldwide, not-for-profit academic oncology clinical research organization of basic and translational scientists, a global oncology network of investigators and an operational clinical trials unit capable of conducting all phases of oncology trials. If you're interested in learning more about TRIO, we'd love to get in touch with you. Contact us at one of our offices to get the conversation started.